Vaccine therapy of colorectal cancer patients with tumor antigens
Cancer vaccines
978-3-8433-5618-3
3843356181
144
2010-11-15
59.00 €
eng
https://images.our-assets.com/cover/230x230/9783843356183.jpg
https://images.our-assets.com/fullcover/230x230/9783843356183.jpg
https://images.our-assets.com/cover/2000x/9783843356183.jpg
https://images.our-assets.com/fullcover/2000x/9783843356183.jpg
For the first time two tumor-associated antigens were evaluated as adjuvant therapy in combination with granulocyte colony stimulating factor (GM-CSF) for patients with colorectal cancer. The first study involved immunization with the protein, carcinoembryonic antigen (CEA) during one year. This vaccination regimen induced a strong immunoglobulin 1 (IgG1) and IgG4 and a moderate IgG2 response against CEA. The humoral as well as the T cell responses were protracted up to 36 months. The dose of CEA had no or modest effect on these responses. The anti-CEA IgG titers related significantly to survival. Functional HLA-DR epitopes of CEA could be defined which may serve as components of a vaccination strategy. The other vaccine strategy consisted of the epithelial cell adhesion molecule (Ep-Cam) expressed as a transgene in a viral vector, ALVAC. Patients were immunized over 6 weeks. No anti-Ep-Cam specific humoral response was induced, but eventually Ep-Cam specific type 1 T cells were induced. Both vaccines were well tolerated. GM-CSF augmented the responses. A low incidence of GM-CSF antibodies that did not neutralize the effect of GM-CSF was observed.
https://morebooks.shop/books/gb/published_by/lap-lambert-academic-publishing/47/products
Clinical disciplines
https://morebooks.shop/store/gb/book/vaccine-therapy-of-colorectal-cancer-patients-with-tumor-antigens/isbn/978-3-8433-5618-3